Toxics
January 24, 2025
Yin Tang, Kang Yang, Jintao Xu et al.
5 citations
Ketamine exposure significantly reduces locomotor activity in juvenile zebrafish, with stronger effects at higher concentrations. Using a high-throughput behavior tracking system, researchers analyzed the movement of 6-day post-fertilization zebrafish exposed to various ketamine concentrations. The study also detected normethketamine, ketamine's primary metabolite, via UPLC-LTQ/Orbitrap HRMS, confirming that zebrafish can metabolize the drug. This integration of behavioral and metabolic profiling demonstrates zebrafish as a useful model for understanding ketamine's neurotoxic and metabolic effects, which may inform research in other vertebrates.
Ecotoxicology and Environmental Safety
January 31, 2024
Sen Zhao, Jinyuan Chen, Chenhao Zhong et al.
3 citations
5-MeO-MiPT, a novel psychoactive tryptamine, caused inhibited movement and anxiety-like behavior in adult zebrafish. Metabolomic analysis after drug injection revealed 22 distinct potential biomarkers and seven significantly altered metabolic pathways, including amino acid, lipid, and energy metabolism. The metabolic changes indicated observable brain damage, especially disruption in the liver-brain pathway, linking the drug's metabolic effects to the anxiety-like behavior.
Ecotoxicology and Environmental Safety
August 30, 2024
Sen Zhao, Meng Liu, Jinyuan Chen et al.
1 citation
5-Methoxy-N-isopropyl-N-methyltryptamine (5-MeO-MiPT), a tryptamine-derived novel psychoactive substance detected in aquatic environments, alters gene expression and disrupts signaling pathways in zebrafish. After 30 days of injection with varying concentrations, RNA-seq, qPCR, metabolomics, and histopathology showed that 5-MeO-MiPT significantly affects the transcription of 13 genes, including ucp1, pet100, grik3, and grik4, via the Gα q/11-PLCβ signaling pathway. The substance inhibits DAG-Ca2+/Pkc/Erk, Pkc/Pla2/PLCs, and Ca2+/CamkII/NMDA pathways while enhancing Ca2+/Creb, mechanisms that may mediate behavioral inhibition and oxidative stress. These findings clarify toxicological and addiction mechanisms of 5-MeO-MiPT and suggest approaches for studying other tryptamine-based NPS and diagnosing liver-brain pathway diseases.
Journal of Applied Toxicology
April 8, 2026
Yin Tang, Yanjiao Wang, Liang Meng et al.
Exposure to the hallucinogenic drug 5-MeO-DiPT for a short period altered 27 metabolites in the brains of zebrafish. Eight metabolites increased and 19 decreased, while nine core metabolic pathways were significantly disrupted. The drug disturbed neurotransmitter balance, amino acid metabolism, and lipid peroxidation, leading to impairments in neural conduction, immune response, and energy metabolism. The findings suggest potential carcinogenic risks and a mechanism for inducing metabolic syndrome.
Zhipu Xuebao
September 19, 2024
Yu-Bin Chen, Jiao-Yuan Yu, Liang Meng et al.
In zebrafish injected with 4-HO-MiPT, movement speed and range dropped sharply, indicating altered locomotor activity. Brain analysis identified 37 differential metabolites—7 elevated and 30 reduced—along with changes in 6 metabolic pathways. Transcriptional levels of genes related to the nervous system decreased, suggesting impacts on neuronal function and synaptic transmission. The findings indicate neurotoxic effects on the zebrafish brain, affecting both nervous and immune systems, and potential carcinogenicity was noted, highlighting the need for risk assessment and regulation.